Skip to main content
Erschienen in: Tumor Biology 6/2011

01.12.2011 | Research Article

The expression and clinical significance of CLIC1 and HSP27 in lung adenocarcinoma

verfasst von: Wei Wang, Xin Xu, Wujun Wang, Wenlong Shao, Liping Li, Weiqiang Yin, Liangchang Xiu, Mingcong Mo, Jin Zhao, Qingyu He, Jianxing He

Erschienen in: Tumor Biology | Ausgabe 6/2011

Einloggen, um Zugang zu erhalten

Abstract

The purpose of this research was to study the roles of chloride intracellular channel protein 1 (CLIC1) and heat shock protein 27 (HSP27) in the clinical pathology of lung adenocarcinoma and to explore whether the expression of CLIC1 and HSP27 can be used as independent factors for the prediction of recurrence and prognosis after radical resection of lung adenocarcinoma. One hundred and three paraffin sections of lung adenocarcinoma tissues were collected, and the expression of CLIC1 and HSP27 was detected in these tumors using immunohistochemistry. The correlation of the expression of these two proteins with clinicopathological parameters and prognosis was statistically analyzed. In the 103 samples, the expression of HSP27 and CLIC1 was strongly positive in 61 (59.2%) and 49 cases (47.6%), respectively. Statistical analysis showed that the expression level of HSP27 did not significantly correlate with the patient’s age, sex, degree of tumor differentiation, T staging of tumors, and TNM staging of tumors (p > 0.05), whereas the expression of CLIC1 did significantly correlate with T staging of tumors (p = 0.029). Univariate analysis indicated that the patient’s ECOG score, T staging, N staging, TNM staging, and CLIC1 expression correlated with prognosis (p = 0.031, 0.001, 0.011, 0.013, and <0.001, respectively). Multivariate statistical analysis showed that age, T staging, and CLIC1 expression were independent associated factors for predicting the 5-year survival rate of patients (p = 0.026, 0.004, and <0.001, respectively). Age, T staging, and CLIC1 expression significantly correlated with the overall survival of post-operative lung adenocarcinoma patients. CLIC1 may be closely associated with the occurrence and development of lung adenocarcinoma and may be used as an effective marker for predicting the prognosis of this disease.
Literatur
1.
Zurück zum Zitat Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef
2.
Zurück zum Zitat Li HL, Qiu Y, Zhang X, et al. Establishment of a lung cancer biobank of a southern Chinese population. J Thorac Dis. 2009;1:17–22. Li HL, Qiu Y, Zhang X, et al. Establishment of a lung cancer biobank of a southern Chinese population. J Thorac Dis. 2009;1:17–22.
3.
Zurück zum Zitat Bethune G, Bethune D, Ridgway N, et al. Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. J Thorac Dis. 2010;2:48–51. Bethune G, Bethune D, Ridgway N, et al. Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. J Thorac Dis. 2010;2:48–51.
4.
Zurück zum Zitat Rena O, Carsana L, Cristina S, et al. Lymph node isolated tumor cells and micrometastases in pathological stage I non-small cell lung cancer: prognostic significance. Eur J Cardiothorac Surg. 2007;32:863–7.PubMedCrossRef Rena O, Carsana L, Cristina S, et al. Lymph node isolated tumor cells and micrometastases in pathological stage I non-small cell lung cancer: prognostic significance. Eur J Cardiothorac Surg. 2007;32:863–7.PubMedCrossRef
5.
Zurück zum Zitat Ruffato A, Mattioli S, Pileri S, et al. Do bone marrow isolated tumor cells influence long-term survival of non-small cell lung cancer? Eur J Cardiothorac Surg. 2009;35:463–8.PubMedCrossRef Ruffato A, Mattioli S, Pileri S, et al. Do bone marrow isolated tumor cells influence long-term survival of non-small cell lung cancer? Eur J Cardiothorac Surg. 2009;35:463–8.PubMedCrossRef
6.
Zurück zum Zitat Shao WL, Wang DY, He JX. The role of gene expression profiling in early-stage non-small cell lung cancer. J Thorac Dis. 2010;2:89–99. Shao WL, Wang DY, He JX. The role of gene expression profiling in early-stage non-small cell lung cancer. J Thorac Dis. 2010;2:89–99.
7.
Zurück zum Zitat Nakamura N, Kobayashi K, Nakamoto M, et al. Identification of tumor markers and differentiation markers for molecular diagnosis of lung adenocarcinoma. Oncogene. 2006;25:4245–55.PubMedCrossRef Nakamura N, Kobayashi K, Nakamoto M, et al. Identification of tumor markers and differentiation markers for molecular diagnosis of lung adenocarcinoma. Oncogene. 2006;25:4245–55.PubMedCrossRef
8.
Zurück zum Zitat Méndez M, Custodio A, Provencio M. New molecular targeted therapies for advanced non-small-cell lung cancer. J Thorac Dis. 2011;3:30–56. Méndez M, Custodio A, Provencio M. New molecular targeted therapies for advanced non-small-cell lung cancer. J Thorac Dis. 2011;3:30–56.
9.
Zurück zum Zitat Liu YF, Xiao ZQ, Li MX, et al. Quantitative proteome analysis reveals annexin A3 as a novel biomarker in lung adenocarcinoma. J Pathol. 2009;217:54–64.PubMedCrossRef Liu YF, Xiao ZQ, Li MX, et al. Quantitative proteome analysis reveals annexin A3 as a novel biomarker in lung adenocarcinoma. J Pathol. 2009;217:54–64.PubMedCrossRef
10.
Zurück zum Zitat Hollander JM, Martin JL, Belke DD. Overexpression of wild- type heat shock protein 27 and a nonphosphorylatable heat shock protein 27 mutant protects against ischemia/reperfusion injury in a transgenic mouse model. Circulation. 2004;110:3544–52.PubMedCrossRef Hollander JM, Martin JL, Belke DD. Overexpression of wild- type heat shock protein 27 and a nonphosphorylatable heat shock protein 27 mutant protects against ischemia/reperfusion injury in a transgenic mouse model. Circulation. 2004;110:3544–52.PubMedCrossRef
11.
Zurück zum Zitat Fincham VJ, James M, Frame MC, et al. Active ERK/MAPkinase15 targeted to newly forming cell-matrix adhesions by integrin engagement and v-Src. EMBOJ. 2000;19:2911–23.CrossRef Fincham VJ, James M, Frame MC, et al. Active ERK/MAPkinase15 targeted to newly forming cell-matrix adhesions by integrin engagement and v-Src. EMBOJ. 2000;19:2911–23.CrossRef
12.
Zurück zum Zitat Lomnytska MI, Becker S, Bodin I, et al. Differential expression of ANXA6, HSP27, PRDX2, NCF2, and TPM4 during uterine cervix carcinogenesis: diagnostic and prognostic value. Br J Canc. 2011;104:110–9.CrossRef Lomnytska MI, Becker S, Bodin I, et al. Differential expression of ANXA6, HSP27, PRDX2, NCF2, and TPM4 during uterine cervix carcinogenesis: diagnostic and prognostic value. Br J Canc. 2011;104:110–9.CrossRef
13.
Zurück zum Zitat Lo Muzio L, Leonardi R, Mariggio MA, et al. HSP 27 as possible prognostic factor in patients with oral squamous cell carcinoma. Histol Histopathol. 2004;9:119–28. Lo Muzio L, Leonardi R, Mariggio MA, et al. HSP 27 as possible prognostic factor in patients with oral squamous cell carcinoma. Histol Histopathol. 2004;9:119–28.
14.
Zurück zum Zitat King KL, Li AF, Chau GY, et al. Prognostic significance of heat shock protein-27 expression in hepatocellular carcinoma and its relation to histologic grading and survival. Cancer. 2000;88:2464–70.PubMedCrossRef King KL, Li AF, Chau GY, et al. Prognostic significance of heat shock protein-27 expression in hepatocellular carcinoma and its relation to histologic grading and survival. Cancer. 2000;88:2464–70.PubMedCrossRef
15.
Zurück zum Zitat Glaessgen A, Jonmarker S, Lindberg A, et al. Heat shock proteins 27, 60 and 70 as prognostic markers of prostate cancer. APMIS. 2008;116:888–95.PubMedCrossRef Glaessgen A, Jonmarker S, Lindberg A, et al. Heat shock proteins 27, 60 and 70 as prognostic markers of prostate cancer. APMIS. 2008;116:888–95.PubMedCrossRef
16.
Zurück zum Zitat Tweedle EM, Khattak I, Ang CW, et al. Low molecular weight heat shock protein HSP27 is a prognostic indicator in rectal cancer but not colon cancer. Gut. 2010;59:1501–10.PubMedCrossRef Tweedle EM, Khattak I, Ang CW, et al. Low molecular weight heat shock protein HSP27 is a prognostic indicator in rectal cancer but not colon cancer. Gut. 2010;59:1501–10.PubMedCrossRef
17.
Zurück zum Zitat Romani AA, Crafa P, Desenzani S, et al. The expression of HSP27 is associated with poor clinical outcome in intrahepatic cholangiocarcinoma. BMC Cancer. 2007;7:232.PubMedCrossRef Romani AA, Crafa P, Desenzani S, et al. The expression of HSP27 is associated with poor clinical outcome in intrahepatic cholangiocarcinoma. BMC Cancer. 2007;7:232.PubMedCrossRef
18.
Zurück zum Zitat Malusecka E, Krzyzowska-Gruca S, Gawrychowski J, et al. Stress proteins HSP27 and HSP70i predict survival in non-small cell lung carcinoma. Anticancer Res. 2008;28:501–6.PubMed Malusecka E, Krzyzowska-Gruca S, Gawrychowski J, et al. Stress proteins HSP27 and HSP70i predict survival in non-small cell lung carcinoma. Anticancer Res. 2008;28:501–6.PubMed
19.
Zurück zum Zitat Tulk BM, Kapadia S, Edwards JC. CLIC1 inserts from the aqueous phase into phospholipid membranes, where it functions as an anion channel. Am J Physiol Cell Physiol. 2002;282:1103–12. Tulk BM, Kapadia S, Edwards JC. CLIC1 inserts from the aqueous phase into phospholipid membranes, where it functions as an anion channel. Am J Physiol Cell Physiol. 2002;282:1103–12.
20.
Zurück zum Zitat Chang YH, Wu CC, Chang KP, et al. Cell secretome analysis using hollow fiber culture system leads to the discovery of CLIC1 protein as a novel plasma marker for nasopharyngeal carcinoma. J Proteome Res. 2009;8:5465–74.PubMedCrossRef Chang YH, Wu CC, Chang KP, et al. Cell secretome analysis using hollow fiber culture system leads to the discovery of CLIC1 protein as a novel plasma marker for nasopharyngeal carcinoma. J Proteome Res. 2009;8:5465–74.PubMedCrossRef
21.
Zurück zum Zitat Shi ZH, Zhao C, Wu H, et al. CLIC1 protein: a candidate prognostic biomarker for malignant-transformed hydatidiform moles. Int J Gynecol Cancer. 2011;21:153–60.PubMedCrossRef Shi ZH, Zhao C, Wu H, et al. CLIC1 protein: a candidate prognostic biomarker for malignant-transformed hydatidiform moles. Int J Gynecol Cancer. 2011;21:153–60.PubMedCrossRef
22.
Zurück zum Zitat Liu XY, Wang YF, Zhu HR. Interaction of Sedlin with PAM14. J Cell Biochem. 2010;109:1129–33.PubMed Liu XY, Wang YF, Zhu HR. Interaction of Sedlin with PAM14. J Cell Biochem. 2010;109:1129–33.PubMed
23.
Zurück zum Zitat Valenzuela SM, Mazzanti M, Tonini R, et al. The nuclear chloride ion channel NCC27 is involved in regulation of the cell cycle. J Physiol. 2000;529:541–52.PubMedCrossRef Valenzuela SM, Mazzanti M, Tonini R, et al. The nuclear chloride ion channel NCC27 is involved in regulation of the cell cycle. J Physiol. 2000;529:541–52.PubMedCrossRef
24.
Zurück zum Zitat Sun HJ, Bahk YY, Choi YR, et al. A proteomic analysis during serial subculture and osteogenic differentiation of human mesenchymal stem cell. J Orthop Res. 2006;24:2059–71.PubMedCrossRef Sun HJ, Bahk YY, Choi YR, et al. A proteomic analysis during serial subculture and osteogenic differentiation of human mesenchymal stem cell. J Orthop Res. 2006;24:2059–71.PubMedCrossRef
25.
Zurück zum Zitat Rahman A, Kumar SG, Kim SW, et al. Proteomic analysis for inhibitory effect of chitosan oligosaccharides on 3T3-L1 adipocyte differentiation. Proteomics. 2008;8:569–81.PubMedCrossRef Rahman A, Kumar SG, Kim SW, et al. Proteomic analysis for inhibitory effect of chitosan oligosaccharides on 3T3-L1 adipocyte differentiation. Proteomics. 2008;8:569–81.PubMedCrossRef
26.
Zurück zum Zitat Chen CD, Wang CS, Huang YH, et al. Overexpression of CLIC1 in human gastric carcinoma and its clinicopathological significance. Proteomics. 2007;7:155–67.PubMedCrossRef Chen CD, Wang CS, Huang YH, et al. Overexpression of CLIC1 in human gastric carcinoma and its clinicopathological significance. Proteomics. 2007;7:155–67.PubMedCrossRef
27.
Zurück zum Zitat Petrova DT, Asif AR, Armstrong VW, et al. Expression of chloride intracellular channel protein 1 (CLIC1) and tumor protein D52 (TPD52) as potential biomarkers for colorectal cancer. Clin Biochem. 2008;41:1224–36.PubMedCrossRef Petrova DT, Asif AR, Armstrong VW, et al. Expression of chloride intracellular channel protein 1 (CLIC1) and tumor protein D52 (TPD52) as potential biomarkers for colorectal cancer. Clin Biochem. 2008;41:1224–36.PubMedCrossRef
28.
Zurück zum Zitat Huang JS, Chao CC, Su TL, et al. Diverse cellular transformation capability of overexpressed genes in human hepatocellular carcinoma. Biochem Biophys Res Commun. 2004;315:4950–8.CrossRef Huang JS, Chao CC, Su TL, et al. Diverse cellular transformation capability of overexpressed genes in human hepatocellular carcinoma. Biochem Biophys Res Commun. 2004;315:4950–8.CrossRef
29.
Zurück zum Zitat Kim W, Oe Lim S, Kim JS, et al. Comparison of proteome between hepatitis B virus- and hepatitis C virus-associated hepatocellular carcinoma. Clin Cancer Res. 2003;9:5493–500.PubMed Kim W, Oe Lim S, Kim JS, et al. Comparison of proteome between hepatitis B virus- and hepatitis C virus-associated hepatocellular carcinoma. Clin Cancer Res. 2003;9:5493–500.PubMed
30.
Zurück zum Zitat Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2:706–14.PubMedCrossRef Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2:706–14.PubMedCrossRef
31.
Zurück zum Zitat Travis WD. World Health Organization, International Agency for Research on Cancer, International Academy of Pathology and International Association for the Study of Lung Cancer. Pathology and genetics of tumours of the lung, pleura, thymus, and heart. Lyon: IARC Press;2004. Travis WD. World Health Organization, International Agency for Research on Cancer, International Academy of Pathology and International Association for the Study of Lung Cancer. Pathology and genetics of tumours of the lung, pleura, thymus, and heart. Lyon: IARC Press;2004.
32.
Zurück zum Zitat Li Z, Zhao X, Bai S, et al. Proteomics identification of cyclophilin a as a potential prognostic factor and therapeutic target in endometrial carcinoma. Mol Cell Proteomics. 2008;7:1810–23.PubMedCrossRef Li Z, Zhao X, Bai S, et al. Proteomics identification of cyclophilin a as a potential prognostic factor and therapeutic target in endometrial carcinoma. Mol Cell Proteomics. 2008;7:1810–23.PubMedCrossRef
33.
Zurück zum Zitat Zhu CQ, Shih W, Ling CH, et al. Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J Clin Pathol. 2006;59:790–800.PubMedCrossRef Zhu CQ, Shih W, Ling CH, et al. Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J Clin Pathol. 2006;59:790–800.PubMedCrossRef
34.
Zurück zum Zitat Kapranos N, Kominea A, Konstantinopoulos PA, et al. Expression of the 27-kDa heat shock protein (HSP27) in gastric carcinomas and adjacent normal, metaplastic, and dysplastic gastric mucosa, and its prognostic significance. J Cancer Res Clin Oncol. 2002;128:426–32.PubMedCrossRef Kapranos N, Kominea A, Konstantinopoulos PA, et al. Expression of the 27-kDa heat shock protein (HSP27) in gastric carcinomas and adjacent normal, metaplastic, and dysplastic gastric mucosa, and its prognostic significance. J Cancer Res Clin Oncol. 2002;128:426–32.PubMedCrossRef
35.
Zurück zum Zitat Selicharová I, Smutná K, Sanda M, et al. 2-DE analysis of a new human cell line EM-G3 derived from breast cancer progenitor cells and comparison with normal mammary epithelial cells. Proteomics. 2007;7:1549–59.PubMedCrossRef Selicharová I, Smutná K, Sanda M, et al. 2-DE analysis of a new human cell line EM-G3 derived from breast cancer progenitor cells and comparison with normal mammary epithelial cells. Proteomics. 2007;7:1549–59.PubMedCrossRef
36.
Zurück zum Zitat Tomonaga T, Matsushita K, Yamaguchi S, et al. Identification of altered protein expression and post-translational modifications in primary colorectal cancer by using agarose two-dimensional gel electrophoresis. Clin Cancer Res. 2004;10:2007–14.PubMedCrossRef Tomonaga T, Matsushita K, Yamaguchi S, et al. Identification of altered protein expression and post-translational modifications in primary colorectal cancer by using agarose two-dimensional gel electrophoresis. Clin Cancer Res. 2004;10:2007–14.PubMedCrossRef
37.
Zurück zum Zitat Yancik R. Cancer burden in the aged: an epidemiologic and demographic overview. Cancer. 1997;80:1273–83.PubMedCrossRef Yancik R. Cancer burden in the aged: an epidemiologic and demographic overview. Cancer. 1997;80:1273–83.PubMedCrossRef
38.
Zurück zum Zitat Janssen-Heijnen ML, Smulders S, Lemmens VE, et al. Effect of comorbidity on the treatment and p rognosis of elderly patientswith non-small cell lung cancer. Thorax. 2004;59:602–7.PubMedCrossRef Janssen-Heijnen ML, Smulders S, Lemmens VE, et al. Effect of comorbidity on the treatment and p rognosis of elderly patientswith non-small cell lung cancer. Thorax. 2004;59:602–7.PubMedCrossRef
39.
Zurück zum Zitat Li Z, Yu Y, Lu J, et al. Analysis of the T descriptors and other prognosis factors in pathologic stage I non-small cell lung cancer in China. J Thorac Oncol. 2009;4:702–9.PubMedCrossRef Li Z, Yu Y, Lu J, et al. Analysis of the T descriptors and other prognosis factors in pathologic stage I non-small cell lung cancer in China. J Thorac Oncol. 2009;4:702–9.PubMedCrossRef
40.
Zurück zum Zitat Chabowski M, Orłowski TM, Rabczenko D. Analysis of prognostic factors and efficacy of surgical treatment for non-small cell lung cancer: department of surgery NTLDRI (1998–1999). Pneumonol Alergol Pol. 2008;76:1–10.PubMed Chabowski M, Orłowski TM, Rabczenko D. Analysis of prognostic factors and efficacy of surgical treatment for non-small cell lung cancer: department of surgery NTLDRI (1998–1999). Pneumonol Alergol Pol. 2008;76:1–10.PubMed
Metadaten
Titel
The expression and clinical significance of CLIC1 and HSP27 in lung adenocarcinoma
verfasst von
Wei Wang
Xin Xu
Wujun Wang
Wenlong Shao
Liping Li
Weiqiang Yin
Liangchang Xiu
Mingcong Mo
Jin Zhao
Qingyu He
Jianxing He
Publikationsdatum
01.12.2011
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 6/2011
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-011-0223-0

Weitere Artikel der Ausgabe 6/2011

Tumor Biology 6/2011 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.